Related Experiment Video
Updated: Jan 11, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.1K
Olezarsen in moderate hypertriglyceridemia: The Essence-TIMI 73b trial
1Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Med (New York, N.Y.)
|November 15, 2025
Summary
Monthly injections of olezarsen, an antisense oligonucleotide, significantly lowered triglycerides and other lipid levels in adults with moderate hypertriglyceridemia over six months. Long-term cardiovascular outcomes and safety are still under investigation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Hypertriglyceridemia is a significant risk factor for cardiovascular disease.
- Apolipoprotein C-III (APOC3) plays a key role in triglyceride metabolism and is a therapeutic target.
- Olezarsen is an antisense oligonucleotide designed to reduce APOC3 production.
Purpose of the Study:
- To evaluate the efficacy of monthly olezarsen injections in adults with moderate hypertriglyceridemia.
- To assess the impact of olezarsen on various lipid parameters over a 6-month period.
Main Methods:
- The Essence-TIMI 73b trial involved monthly subcutaneous injections of olezarsen.
- The study duration was 6 months.
- Participants had moderate hypertriglyceridemia.
Main Results:
- Olezarsen treatment led to a significant decrease in triglyceride concentrations.
- Key lipid markers, including apolipoprotein C-III, apolipoprotein B, non-HDL-C, VLDL cholesterol, and remnant cholesterol, were significantly reduced.
- High-density lipoprotein (HDL) cholesterol levels increased with olezarsen treatment.
Conclusions:
- Monthly olezarsen injections effectively improve lipid profiles in adults with moderate hypertriglyceridemia.
- Further studies are needed to determine the long-term safety and cardiovascular outcomes associated with olezarsen therapy.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
428
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
428
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
447
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
447
01:20Antiepileptic Drugs: Potassium Channel Activators
616
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
616
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
542
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
542